Erratum: Chronic idiopathic myelofibrosis expressing a novel type of TEL-PDGFRB chimaera responded to imatinib mesylate therapy (Leukemia (2007) vol. 21 (190-192) 10.1038/sj.leu.2404397);Chronic idiopathic myelofibrosis expressing a novel type of TEL-PDGFRB chimaera responded to imatinib mesylate therapy [9]

Leukemia

Volumn 21, Issue 1, 2007, Pages 190-192

  Tokita, K ^a   Maki, K ^a   Tadokoro, J ^a   Nakamura, Y ^a   Arai, Y ^a   Sasaki, K ^a   Eguchi Ishimae, M ^a   Eguchi, M ^a   Mitani, K ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; IDARUBICIN; IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CASE REPORT; CHIMERA; DISEASE COURSE; DRUG MEGADOSE; DRUG RESPONSE; EPISTAXIS; GINGIVA BLEEDING; HEPATOSPLENOMEGALY; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; LETTER; MALE; MULTIPLE CYCLE TREATMENT; MYELOID METAPLASIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

EID: 33845545767     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2405099     Document Type: Erratum

References (8)

1. Cross NC, Reiter A. Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia 2002; 16: 1207-1212.
2. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994; 77: 307-316.
3. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-1214.
4. Carroll M, Tomasson MH, Barker GF, Golub TR, Gilliland DG. The TEL/ platelet-derived growth factor β receptor (PDGFβR) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGFβR kinase-dependent signaling pathways. Proc Natl Acad Sci USA 1996; 93: 14845-14850.
5. Eguchi M, Eguchi-Ishimae M, Tojo A, Morishita K, Suzuki K, Sato Y et al. Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). Blood 1999; 93: 1355-1363.
6. Eguchi M, Eguchi-Ishimae M, Green A, Enver T, Greaves M. Directing oncogenic fusion genes into stem cells via an SCL enhancer. Proc Natl Acad Sci USA 2005; 102: 1133-1138.
7. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56: 100-104.
8. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002; 347: 481-487.